CollPlant Biotechnologies (CLGN) Non-Current Debt (2017 - 2018)
CollPlant Biotechnologies' (CLGN) quarterly Non-Current Debt came in at $58000.0 in Q2 2018, down 98.41% on a QoQ basis from $3.6 million in Q4 2017.
CollPlant Biotechnologies (CLGN) Non-Current Debt (2017 - 2018) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 2 years of Non-Current Debt data on file, last reported at $58000.0 in Q2 2018.
- Quarterly Non-Current Debt changed N/A year-over-year to $58000.0 in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $58000.0 (changed N/A YoY) and the FY2017 annual result came in at $3.6 million, changed N/A from the prior year.
- Non-Current Debt eased to $58000.0 in Q2 2018, from $3.6 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $3.6 million in Q4 2017 to a low of $58000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 58,000.00 |
| Dec 31, 2017 | 3.65 Mn |